InVivoMAb Anti-Mouse CD274/PD-L1/B7-H1 Antibody (10F.9G2)(VMJ70102)抗体

InVivoMAb Anti-Mouse CD274/PD-L1/B7-H1 Antibody (10F.9G2)(VMJ70102)抗体

一、中文名称：InVivoMAb Anti-Mouse CD274/PD-L1/B7-H1 Antibody (10F.9G2)(VMJ70102)，抗小鼠PDL1抗体，体内中和抗体/活性抗体

 

二、产品描述

PD-L1（程序性死亡配体1，Programmed Death-Ligand 1），也称为CD274或B7-H1，是一种在多种细胞类型表面表达的免疫调节蛋白。它主要通过与T细胞上的PD-1（程序性死亡受体1）结合，抑制T细胞活性并下调免疫反应，从而在维持外周耐受性和防止自身免疫方面发挥重要作用。在肿瘤微环境中，癌细胞常常高表达PD-L1，利用这种机制逃避免疫系统的识别和攻击。近年来，针对PD-L1及其受体PD-1的免疫检查点抑制剂（如阿特珠单抗和度伐利尤单抗）已被广泛应用于多种癌症治疗，包括非小细胞肺癌、黑色素瘤和膀胱癌等。这些药物通过阻断PD-L1与PD-1的结合，恢复T细胞对肿瘤细胞的杀伤能力，显著提高了患者的生存率和生活质量。

 

三、产品详情

名称：InVivoMAb Anti-Mouse CD274/PD-L1/B7-H1 Antibody (10F.9G2) (VMJ70102)

别名： HPD-L1，Programmed Cell Death 1 Ligand 1，PDCD1L1，B7H1，PDL1，Programmed Death Ligand 1，B7-H1，B7-H，B7-H1 Antigen，CD274，B7 homolog 1，PDCD1 ligand 1，PD-L1，PDCD1LG1，CD274 Molecule，CD274 Antigen

货号：VMJ70102

种属反应性：Mouse

宿主：Rat

同种型：IgG2b

克隆类型：Monoclonal

靶标：Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, Cd274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1

浓度：0.6 mg/ml

内毒素水平：Please contact with the lab for this information.

纯度：>95% as determined by SDS-PAGE.

纯化方式：Protein A/G purified from cell culture supernatant.

Accession号：Q9EP73

克隆号：10F.9G2

应用：FCM, Neutralization

状态：Liquid

保存溶液：0.01M PBS, pH 7.4.

稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

 

四、参考文献：

CD274 (PD-L1) negatively regulates M1 macrophage polarization in ALI/ARDS. PMID: 38440722

CD274 (PD-L1) Methylation is an Independent Predictor for Bladder Cancer Patients' Survival. PMID: 35020560

PD-L1 degradation pathway and immunotherapy for cancer. PMID: 33159034

USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. PMID: 31399419

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA. PMID: 37425040

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. PMID: 37868689

Tumor Mutational Burden and Response Rate to PD-1 Inhibition. PMID: 29262275

Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. PMID: 34038734

CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. PMID: 27855694

PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition. PMID: 31507611

PD-L1 expression in human cancers and its association with clinical outcomes. PMID: 27574444

PD-L1 immunohistochemistry: Clones, cutoffs, and controversies. PMID: 35332576

PD-L1-specific T cells. PMID: 26724936

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. PMID: 35078921

PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. PMID: 32290052

B7-H1 pathway and its role in the evasion of tumor immunity. PMID: 12721664

B7-H1/PD-1 blockade therapy in urological malignancies: current status and future prospects. PMID: 26045125

The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. PMID: 33536783

Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. PMID: 21730022

Therapeutic targeting of B7-H1 in breast cancer. PMID: 21870995

Mechanisms Controlling PD-L1 Expression in Cancer. PMID: 31668929

Immunology of B7-H1 and its roles in human diseases. PMID: 14686489

 

详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司

 

武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。

试剂 | 耗材 | 定制 | 实验服务 | 供应链

免费热线：027-65279366 /18108604356